



Review

Amino acid sensing and regulation of mTORC1

Lijun Yan^{a,**}, Richard F. Lamb^{b,*}^a School of Pharmacy, Harbin University of Commerce, Harbin, 150076, PR China^b Department of Oncology, University of Alberta, Edmonton, Alberta, Canada

ARTICLE INFO

Article history:

Available online 10 February 2012

Keywords:

Amino acid
Sensing
Regulation
mTORC1

ABSTRACT

Amino acids play fundamental roles in the cell both as the building blocks of new proteins and as metabolic precursors. To adapt to their limitation during periods of protein starvation, multiple adaptive mechanisms have evolved, including a rapid cessation of new protein synthesis, an increase in amino acid biosynthesis and transport, and autophagy. Here, we discuss what we currently know about how amino acid limitation is sensed, and how this sensing might be transmitted to mTORC1 to regulate protein synthesis and autophagy.

© 2012 Elsevier Ltd. All rights reserved.

Contents

1. Introduction.....	621
2. Amino acid sensing and the mTORC1 pathway.....	621
3. Amino acid sensing and GCN2 signaling.....	622
4. Amino acids insufficiency: are some amino acids more important than others?.....	622
5. Lysosome-associated machinery for amino acid sensing.....	623
6. Conclusions and perspectives.....	623
Acknowledgments.....	623
References.....	623

1. Introduction

In multicellular organisms homeostatic mechanisms evolved that permit survival of the organism when faced with a broad range of environmental fluctuations, including large changes in temperature, salinity, acidity and nutrient supply. In the face of fluctuating supply of amino acid nutrients, mechanisms evolved that both suppressed energy-consuming processes such as new protein synthesis and augmented redistribution of existing resources *via* proteolysis. Both processes are likely critical in maintaining overall cell mass and viability, particularly given the large contribution of protein to a cell's dry mass [1]. Amino acid availability is one of the major determinants of normal organismal growth and impacts on both regulation of protein synthesis and upon proteolysis [2,3].

Restriction of one or several amino acids has been found to have pleiotropic cellular effects, depending on the type of cell, organism

and timeframe studied (reviewed in [4]). These include: a general but incomplete inhibition of protein synthesis, increased expression of amino acid biosynthetic genes, and enhanced degradation of proteins through ubiquitin–proteasome systems and autophagy [5–7]. Conversely, at least in higher organisms, amino acid excess has been found to be associated with decreased expression of proteins involved in ubiquitin–proteasome and autophagy protein degradation pathways and a reduction in the level of mRNAs encoding ubiquitin ligases [8,9]. Given that many cancer cells also adapt their metabolism when faced with a limited blood supply and insufficient nutrients to support rapid tumor growth [10], there is much interest in understanding the mechanisms responsible for amino acid sensing and their potential for modulation in anti-cancer therapies.

2. Amino acid sensing and the mTORC1 pathway

The energy-costly anabolic process of protein synthesis must by necessity be coupled to the energy status of the cell and to ambient nutrient levels. In isolated cells, amino acid withdrawal leads to a rapid suppression of protein synthesis and enhanced degradation of proteins [6,11]. In mammalian cells, amino acids

* Corresponding author. Tel.: +1 780 432 8207; fax: +1 780 432 8892.

** Corresponding author. Tel.: +86 451 8486 9718; fax: +86 451 8486 9718.

E-mail addresses: lijun.yann@hotmail.com (L. Yan),rflamb@ualberta.ca (R.F. Lamb).

sufficiency promote protein synthesis in part by inhibiting the binding of the translation repressor 4EBP1 (eukaryotic initiation factor eIF4E-binding protein-1) to initiation factor eIF4E and by stimulating the activity of ribosomal protein S6 kinase (S6K), and both these events are reversed by amino acid restriction [11]. These two signaling events require the activity of TOR (target of rapamycin), as 4EBP1 and S6K are the most well-studied downstream effectors for mTORC1, the rapamycin-sensitive mTOR complex [11]. TOR initially came to light as the cellular target for the immunosuppressant drug rapamycin [12]. Rapamycin treatment mimics a nutrient deprivation-like signal in budding yeast *Saccharomyces cerevisiae*, suggesting that TOR functionally mediates some responses to nutrient cues. TOR is structurally and functionally conserved from yeast to human [13] and is a member of the family of large phosphoinositide-3-kinase (PIK)-related kinases that possess protein kinase, rather than lipid kinase, activity. TOR has a C-terminal protein kinase domain with similarity to the lipid kinase PI3K, and repeated N-terminal HEAT segments that are thought to mediate its interaction with binding partners. mTOR (mammalian TOR) exists in two distinct functional complexes, mTOR complex 1 (mTORC1) and mTORC2. Rapamycin, complexed with the polypeptide FKBP12, binds directly to TORC1 and inhibits many (but not all [14,15]) of TORC1's signaling functions [16,17].

The core mTORC1 proteins are composed of mTOR, regulatory-associated protein of mTOR (Raptor), and mammalian lethal with Sec13 protein 8 (mLST8, also known as GβL) [18–20], while the core mTORC2 proteins are mTOR, Rictor (RPTOR-independent companion of mTOR), mSIN1 (mammalian stress-activated protein kinase interacting protein), and GβL [21–23]. Raptor regulates mTORC1 assembly and is thought to also recruit substrates such as 4E-BP1 and S6K [18,19]. Recent work has shown that Raptor also mediates interactions with the scaffold protein p62 involved in autophagosome formation, and with the Rag family of heterodimeric GTPases, suggesting that it likely plays an important role in directing the subcellular localization of mTORC1 [24,25].

Mitogens and hormones, such as insulin or polypeptide growth factors, or agents such as bacterial lipopolysaccharide (LPS) have been known for some time to be insufficient to drive full mTORC1 activation in the absence of amino acids, indicating that mTORC1 is able to monitor a deficiency in amino acids and that this inhibitory “sensing” acts dominantly to opposing stimulatory signals [11,26]. Insulin and other growth factors promote mTORC1 activation through mechanisms that mainly converge on inhibiting the tuberous sclerosis heterodimeric complex (TSC1/TSC2), thereby stimulating (in a manner that is currently unclear) GTP loading of the small GTPase Rheb (Ras homolog enriched in brain) [27–29]. The GTP-charged form of Rheb is a positive regulator of mTORC1, however, Rheb does not activate TORC1 signaling by modulating intracellular amino acid levels [30]. Both overexpressed wild-type Rheb (which is mainly GTP loaded [31]) or nucleotide-free Rheb have been shown to bind to mTOR at its catalytic domain under particular conditions, and Rheb has been shown by one group to stimulate mTORC1's weak kinase activity measured *in vitro*, and by another to promote substrate recruitment *via* raptor [31–33]. However, thus far an interaction between endogenous Rheb and mTORC1 has not been demonstrated during stimulation of mTORC1 by growth factors or amino acids.

Although amino acid withdrawal can lead to a decrease in Rheb-GTP levels in some cell types [34], Rheb-GTP levels have been shown not to decline in TSC1- or TSC2-null cells following amino acid withdrawal despite an inhibition of mTORC1, as determined by a decline in S6K1 T389 phosphorylation. Thus it has been suggested that amino acid nutrients act on mTORC1 signaling *via* a distinct signaling pathway [35,36]. Indeed, TORC1 in *S. cerevisiae* responds to nutrients [37] despite the absence of TSC orthologs.

3. Amino acid sensing and GCN2 signaling

The general control nonrepressed (GCN2) pathway, and its central component, the protein kinase GCN2 is a conserved pathway important for monitoring nutrient availability. Uncharged tRNAs that accumulate upon amino acid limitation bind to a tRNA-synthase-like domain in GCN2, inducing a conformational change that permits kinase activation, although it is likely that other activation mechanisms exist as GCN2 can also be rapidly activated by UV [38,39]. GCN2 was originally described in *S. Cerevisiae* as a kinase that phosphorylates the translational initiation factor eIF-2α [40], thereby sequestering the exchange factor for eIF2α, eIF2B, and decreasing the assembly of 43S initiation complexes under conditions of amino acid deprivation [41]. GCN2 activation was found to increase expression of a large set of genes, including many encoding enzymes of amino acid biosynthesis, through the increased translation of a transcriptional factor, GCN4 [42,40]. Thus, uncharged tRNA accumulating in amino acid-deprived cells activates GCN2, which phosphorylates the initiation factor eIF2α (eukaryotic initiation factor 2α) [43]. GCN2 together with GCN1, an *in vivo* activator and binding protein for of the kinase [44,45], are conserved from yeast to mammals. In mammalian cells, phosphorylation of eIF2α leads to preferential translation of a distinct transcription factor, activating transcription factor (ATF4), with the consequent induction of genes for amino acids biosynthesis and transport [46–48].

A major unresolved question remains whether the amino acid sensing mechanism controlled by GCN2 acts to inhibit mTORC1. On the face of it, linking an existing conserved sensor of amino acid deficiency to mTORC1 *via* an inhibitory interaction would make good use of an existing mechanism to respond to amino acid limitation. Indeed some evidence for GCN2 as an upstream inhibitor of mTOR under conditions of leucine deprivation have been provided [49,50]. However a major stumbling block to the GCN2 and mTORC1 systems being functionally linked is the finding that uncharged tRNA – the only well-described mechanism of GCN2 activation – have been reported not to be induced during the time frame of mTORC1 inhibition [51]. However, at least in *S. cerevisiae*, and using a sensitive method to detect changes in tRNA charging, it is now clear that leucine deprivation indeed does lead to the rapid appearance of uncharged tRNA^{Leu} species [52]. However, whether this rapid appearance of uncharged tRNA species also occurs in mammalian cells and might thereby allow a rapid enough activation of GCN2 to inhibit mTORC1, is not known.

4. Amino acids insufficiency: are some amino acids more important than others?

During development TOR is essential for growth, but upon completion of development it restricts lifespan, and its activation is thought to contribute to age-related diseases such as cancer, metabolic syndrome, atherosclerosis, hypertension and hypertrophic heart [53–55]. Therefore extensive research efforts have centered on understanding how amino acids, and their sensors and transporters, regulate TOR. Work in *Drosophila* and studies in mice have shown that a TOR-dependent sensor for amino acids exists in specific neuronal cells—hypothalamic cells in the mouse and neuroendocrine cells in *Drosophila*. These cells sense variations in circulating amino-acid levels and in turn regulate feeding behavior [56,57]. Aside from amino acid detection by these specific cells and their contribution to the behavioral responses involved in food intake, specific amino acids have been shown to impact on growth and to alter metabolic homeostasis. Indeed, the essential amino acid leucine appears to act upon metabolism at multiple levels and is critical in most cells for mTORC1 activation [11,58,59]. In many mammalian cell types cellular entry of leucine primarily

depends on the system L transporters, which consist of a promiscuous single-pass transmembrane glycoprotein (CD98) and one of six multipass transmembrane amino acid permeases (L-type amino acid transporter 1, 2, 3 and 4) [60–63]. In some cells, a bidirectional L amino acid transporter system has been identified that transports leucine and other essential amino acids (EAA) to regulate mTORC1 and autophagy via efflux of L-glutamine [64]. In *Drosophila*, a homolog of the heterodimer of CD98 and LAT-1 and -2, *Minidiscs*, is also likely to be involved in leucine transport [65,66]. Underscoring the importance of leucine in regulating TORC1, S6K1 was found to be activated by microinjection of leucine into *Xenopus* oocytes that normally lack the system L transporter [67].

However it should be noted that another critical amino acid for activation of mTORC1 highlighted by some studies is arginine [11,26,68]. Studies in *Drosophila* first indicated a role for arginine and/or lysine transport in mTORC1 activation as *Slimfast*, a transporter of arginine and lysine, was shown to be critical for normal body size and activation of mTORC1 in the *Drosophila* fat body [69]. We have also observed that removal of either leucine or arginine results in S6K1 T389 dephosphorylation within 5–10 min in HEK293T cells, and S6K1 is rephosphorylated within a similar time frame upon supplementation of the omitted amino acid (Yan and Lamb, unpublished observations).

5. Lysosome-associated machinery for amino acid sensing

The proton-assisted SLC36 amino acid transporters (PATs) were identified on the surface of mammalian lysosomes, at the plasma membrane and in endosomal compartments, suggesting that they could act via an intracellular mechanism [70–72]. Two PAT-related transporters in *Drosophila*, CG3424 and CG1139, have been shown to mediate growth [73]. Like CG1139, human PAT1 and PAT2 specifically transport alanine, glycine and proline in an electrogenic and proton-stimulated fashion, rather than leucine and arginine important for mTORC1 signaling [73,74]. The mechanistic features for the PATs acting on mTORC1 signaling remain to be established, although PATs might modulate the activity of mTORC1 not by transporting amino acids into the cell but by modulating an intracellular response to amino acids [75]. Interestingly, PAT1 is concentrated in intracellular compartments, including late endosomes/lysosomes, wherein mTOR shuttles upon amino-acid stimulation [25,76].

In two previous reports, both biochemical and genetic studies demonstrated that mammalian Rag (Ras-related GTPases) GTPases and yeast Gtr1/2 play a crucial role in amino acid signaling to TOR as heterodimeric complexes [25,77]. Amino acid sufficiency has been shown to induce the movement of some fraction of mTORC1 to lysosomal membranes [76,78], where the Rag proteins reside [78]. A complex encoded by MAPKSP1 (MP1), ROBLD3 (p14), and c11orf59 (p18) (termed the “Ragulator”) was identified as a new component of the mTORC1 pathway that interacts with the Rag GTPases, and is essential for localizing them and mTORC1 to the lysosomal surface [78]. p18 directly interacts with the Rag GTPases, as well as with p14 and MP1 [79] and together this complex appears necessary for the activation of the mTORC1 pathway by amino acids [78]. By screening for genes thought to be involved in lysosomal biogenesis and function for effects on mTORC1, Sabatini and co-workers have latterly identified the vacuolar H⁺-adenosine triphosphatase ATPase (v-ATPase) as required for amino acid-induced activation of mTORC1 [80]. Amino acids were found to regulate the interaction between the V1 domain of v-ATPase and Ragulator and Rag GTPases [80]. However, unlike the Ragulator [78], the v-ATPase appears not to be necessary for anchoring the Rag GTPases to the lysosomal surface [80].

Given that mTORC1 can localize to lysosomes in amino acid replete conditions, it would appear to be a strong possibility that

mTORC1 senses amino acid deficiency there, as has been suggested [80]. However, given that amino acid limitation is a stress response [4], another possibility is that it is energetically-favorable to localize mTORC1 to lysosomes during times of plentiful nutrients in preparation for some important immediate function that mTORC1 needs to provide there when amino acids are acutely limited. Surprisingly, both amino acid replete conditions and conditions in which mTORC1 is acutely inhibited with rapamycin lead to increased mTORC1 recruitment to lysosomes [81], while colocalization of mTORC1 with lysosomes can still be observed under starvation conditions that inhibit mTORC1’s activation of p70S6K1 [82], indicating that mTORC1 activity and lysosomal association are not strictly coupled. Recently, mTORC1 activity has also been linked with lysosomal biogenesis via the activation of phosphorylation of TFE3, a transcription factor that activates a program of gene expression critical for lysosomal biogenesis [83,84], a process that may be critical to restore homeostasis following lysosomal consumption after fusion with autophagosomes [85]. Thus it seems plausible that the localization of mTORC1 to lysosomes may not be strictly linked with amino acid sensing at the lysosomal surface.

6. Conclusions and perspectives

A number of other genes have also been implicated in the process of intracellular nutrient sensing (reviewed in [30,86]). Plausible evidence implicating MAP4K3 [35,87–89], Vps34 (Vacuolar Protein Sorting 34) [36,90] and phospholipase D (PLD [91,92]) have been presented in mechanisms relating amino acid sufficiency to mTORC1 activation. The precise mechanisms involved in connecting these events to mTORC1 and an amino acid sensor still remain for the large part undiscovered. It should be noted that, with the exceptions of MAP4K3 that was isolated in a sensitized genetic screen for protein kinase involvement [35], and the Rag GTPases [77] in a similar screen for small GTPases, unbiased genetic screens have been relatively unsuccessful in identifying components of the nutrient input to mTORC1, suggesting either that multiple levels of redundancy and back-up systems may have evolved to allow mTORC1 to sense amino acids, or that key components in this response play essential roles in viability. Connecting the known components and mechanisms together to create a consistent model of how a cell senses amino acids and transmits this information to mTORC1 remains a major challenge for biologists interested in growth control, but is one that is likely to lead to new insights into disease processes involving aberrant growth and nutrient utilization.

Acknowledgments

This work was supported by the Alberta Cancer Foundation (R.F. Lamb), and the Heilongjiang Provincial Department of Education funded research projects overseas scholars and Long Jiang Scholars Foundation (L. Yan).

References

- [1] Gaub J, Auer G, Zetterberg A. Quantitative cytochemical aspects of a combined feulgen-naphthol yellow S staining procedure for the simultaneous determination of nuclear and cytoplasmic proteins and DNA in mammalian cells. *Exp Cell Res* 1975;92(2):323–32.
- [2] Paddon-Jones D, Sheffield-Moore M, Zhang XJ, Volpi E, Wolf SE, Aarsland A, et al. Amino acid ingestion improves muscle protein synthesis in the young and elderly. *Am J Physiol Endocrinol Metab* 2004;286(3):E321–8.
- [3] Nakashima K, Ishida A, Yamazaki M, Abe H. Leucine suppresses myofibrillar proteolysis by down-regulating ubiquitin-proteasome pathway in chick skeletal muscles. *Biochem Biophys Res Commun* 2005;336(2):660–6.
- [4] Kilberg MS, Pan YX, Chen H, Leung-Pineda V. Nutritional control of gene expression: how mammalian cells respond to amino acid limitation. *Annu Rev Nutr* 2005;25:59–85.

- [5] Du M, Zhu MJ, Means WJ, Hess BW, Ford SP. Nutrient restriction differentially modulates the mammalian target of rapamycin signaling and the ubiquitin–proteasome system in skeletal muscle of cows and their fetuses. *J Anim Sci* 2005;83(1):117–23.
- [6] Rabinowitz JD, White E. Autophagy and metabolism. *Science* 2010;330(6009):1344–8.
- [7] Natarajan K, Meyer MR, Jackson BM, Slade D, Roberts C, Hinnebusch AG, et al. Transcriptional profiling shows that Gcn4p is a master regulator of gene expression during amino acid starvation in yeast. *Mol Cell Biol* 2001;21(13):4347–68.
- [8] Chotechuan N, Azzout-Marniche D, Bos C, Chaumontet C, Gaudichon C, Tome D. Down-regulation of the ubiquitin–proteasome proteolysis system by amino acids and insulin involves the adenosine monophosphate-activated protein kinase and mammalian target of rapamycin pathways in rat hepatocytes. *Amino Acids* 2011;41(2):457–68.
- [9] Herningtyas EH, Okimura Y, Handayaningsih AE, Yamamoto D, Maki T, Iida K, et al. Branched-chain amino acids and arginine suppress MaFbx/atrogin-1 mRNA expression via mTOR pathway in C2C12 cell line. *Biochim Biophys Acta* 2008;1780(10):1115–20.
- [10] Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. *Science* 2009;324(5930):1029–33.
- [11] Hara K, Yonezawa K, Weng QP, Kozłowski MT, Belham C, Avruch J. Amino acid sufficiency and mTOR regulate p70S6 kinase and eIF-4E BP1 through a common effector mechanism. *J Biol Chem* 1998;273(23):14484–94.
- [12] Heitman J, Movva NR, Hall MN. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. *Science* 1991;253(5022):905–9.
- [13] Wullschlegel S, Loewith R, Hall MN. TOR signaling in growth and metabolism. *Cell* 2006;124(3):471–84.
- [14] Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. *J Biol Chem* 2009;284(12):8023–32.
- [15] Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Ruggero D, et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. *PLoS Biol* 2009;7(2):e38.
- [16] Chen J, Zheng XF, Brown EJ, Schreiber SL. Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue. *Proc Natl Acad Sci USA* 1995;92(11):4947–51.
- [17] Choi J, Chen J, Schreiber SL, Clardy J. Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. *Science* 1996;273(5272):239–42.
- [18] Hara K, Maruki Y, Long X, Yoshino K, Oshiro N, Hidayat S, et al. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. *Cell* 2002;110(2):177–89.
- [19] Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H, et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. *Cell* 2002;110(2):163–75.
- [20] Kim DH, Sarbassov DD, Ali SM, Latek RR, Guntur KV, Erdjument-Bromage H, et al. Gbeta1, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. *Mol Cell* 2003;11(4):895–904.
- [21] Jacinto E, Facchinetti V, Liu D, Soto N, Wei S, Jung SY, et al. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. *Cell* 2006;127(1):125–37.
- [22] Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. *Curr Biol* 2004;14(14):1296–302.
- [23] Yang Q, Inoki K, Ikenoue T, Guan KL. Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity. *Genes Dev* 2006;20(20):2820–32.
- [24] Duran A, Amanchy R, Linares JF, Joshi J, Abu-Baker S, Porollo A, et al. p62 is a key regulator of nutrient sensing in the mTORC1 pathway. *Mol Cell* 2011;44(1):134–46.
- [25] Sancak Y, Peterson TR, Shaul YD, Lindquist RA, Thoreen CC, Bar-Peled L, et al. The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. *Science* 2008;320(5882):1496–501.
- [26] Mieulet V, Yan L, Choisy C, Sully K, Procter J, Kouroumalis A, et al. TPL-2-mediated activation of MAPK downstream of TLR4 signaling is coupled to arginine availability. *Sci Signal* 2010;3(135):ra61.
- [27] Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. *N Engl J Med* 2006;355(13):1345–56.
- [28] Inoki K, Corradetti MN, Guan KL. Dysregulation of the TSC-mTOR pathway in human disease. *Nat Genet* 2005;37(1):19–24.
- [29] Kwiatkowski DJ, Manning BD. Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways. *Hum Mol Genet* 2005;14 Spec. No. 2: R251–8.
- [30] Avruch J, Long X, Ortiz-Vega S, Rapley J, Papageorgiou A, Dai N. Amino acid regulation of TOR complex 1. *Am J Physiol Endocrinol Metab* 2009;296(4):E592–602.
- [31] Long X, Lin Y, Ortiz-Vega S, Yonezawa K, Avruch J. Rheb binds and regulates the mTOR kinase. *Curr Biol* 2005;15(8):702–13.
- [32] Sancak Y, Thoreen CC, Peterson TR, Lindquist RA, Kang SA, Spooner E, et al. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. *Mol Cell* 2007;25(6):903–15.
- [33] Sato T, Nakashima A, Guo L, Tamanoi F. Specific activation of mTORC1 by Rheb G-protein in vitro involves enhanced recruitment of its substrate protein. *J Biol Chem* 2009;284(19):12783–91.
- [34] Rocco M, Bos JL, Zwartkruis FJ. Regulation of the small GTPase Rheb by amino acids. *Oncogene* 2006;25(5):657–64.
- [35] Findlay GM, Yan L, Procter J, Mieulet V, Lamb RF. A MAP4 kinase related to Ste20 is a nutrient-sensitive regulator of mTOR signalling. *Biochem J* 2007;403(1):13–20.
- [36] Nobukuni T, Joaquin M, Rocco M, Dann SG, Kim SY, Gulati P, et al. Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase. *Proc Natl Acad Sci USA* 2005;102(40):14238–43.
- [37] Binda M, Peli-Gullis MP, Bonfils G, Panchaud N, Urban J, Sturgill TW, et al. The Vam6 GEF controls TORC1 by activating the EGO complex. *Mol Cell* 2009;35(5):563–73.
- [38] Deng J, Harding HP, Raught B, Gingras AC, Berlanga JJ, Scheuner D, et al. Activation of GCN2 in UV-irradiated cells inhibits translation. *Curr Biol* 2002;12(15):1279–86.
- [39] Wek SA, Zhu S, Wek RC. The histidyl-tRNA synthetase-related sequence in the eIF-2 alpha protein kinase GCN2 interacts with tRNA and is required for activation in response to starvation for different amino acids. *Mol Cell Biol* 1995;15(8):4497–506.
- [40] Hinnebusch AG. Translational regulation of GCN4 and the general amino acid control of yeast. *Annu Rev Microbiol* 2005;59:407–50.
- [41] Clemens MJ. Initiation factor eIF2 alpha phosphorylation in stress responses and apoptosis. *Prog Mol Subcell Biol* 2001;27:57–89.
- [42] Dever TE, Feng L, Wek RC, Cigan AM, Donahue TF, Hinnebusch AG. Phosphorylation of initiation factor 2 alpha by protein kinase GCN2 mediates gene-specific translational control of GCN4 in yeast. *Cell* 1992;68(3):585–96.
- [43] Zhang P, McGrath BC, Reinert J, Olsen DS, Lei L, Gill S, et al. The GCN2 eIF2alpha kinase is required for adaptation to amino acid deprivation in mice. *Mol Cell Biol* 2002;22(19):6681–8.
- [44] Marton MJ, Crouch D, Hinnebusch AG. GCN1, a translational activator of GCN4 in *Saccharomyces cerevisiae*, is required for phosphorylation of eukaryotic translation initiation factor 2 by protein kinase GCN2. *Mol Cell Biol* 1993;13(6):3541–56.
- [45] Garcia-Barrio M, Dong J, Ufano S, Hinnebusch AG. Association of GCN1–GCN20 regulatory complex with the N-terminus of eIF2alpha kinase GCN2 is required for GCN2 activation. *EMBO J* 2000;19(8):1887–99.
- [46] Harding HP, Novoa I, Zhang Y, Zeng H, Wek R, Schapira M, et al. Regulated translation initiation controls stress-induced gene expression in mammalian cells. *Mol Cell* 2000;6(5):1099–108.
- [47] Proud CG. eIF2 and the control of cell physiology. *Semin Cell Dev Biol* 2005;16(1):3–12.
- [48] Ameri K, Harris AL. Activating transcription factor 4. *Int J Biochem Cell Biol* 2008;40(1):14–21.
- [49] Anthony TG, McDaniel BJ, Byerley RL, McGrath BC, Cavener DR, McNurlan MA, et al. Preservation of liver protein synthesis during dietary leucine deprivation occurs at the expense of skeletal muscle mass in mice deleted for eIF2 kinase GCN2. *J Biol Chem* 2004;279(35):36553–61.
- [50] Xiao F, Huang Z, Li H, Yu J, Wang C, Chen S, et al. Leucine deprivation increases hepatic insulin sensitivity via GCN2/mTOR/S6K1 and AMPK pathways. *Diabetes* 2011;60(3):746–56.
- [51] Dennis PB, Jaeschke A, Saitoh M, Fowler B, Kozma SC, Thomas G. Mammalian TOR: a homeostatic ATP sensor. *Science* 2001;294(5544):1102–5.
- [52] Zaborske JM, Narasimhan J, Jiang L, Wek SA, Dittmar KA, Freimoser F, et al. Genome-wide analysis of tRNA charging and activation of the eIF2 kinase Gcn2p. *J Biol Chem* 2009;284(37):25254–67.
- [53] Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. *Nature* 2009;460(7253):392–5.
- [54] Selman C, Tullet JM, Wieser D, Irvine E, Lingard SJ, Choudhury AI, et al. Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. *Science* 2009;326(5949):140–4.
- [55] Blagosklonny MV, Hall MN. Growth and aging: a common molecular mechanism. *Aging* 2009;1(4):357–62.
- [56] Cota D, Proulx K, Smith KA, Kozma SC, Thomas G, Woods SC, et al. Hypothalamic mTOR signaling regulates food intake. *Science* 2006;312(5775):927–30.
- [57] Wu Q, Zhang Y, Xu J, Shen P. Regulation of hunger-driven behaviors by neural ribosomal S6 kinase in *Drosophila*. *Proc Natl Acad Sci USA* 2005;102(37):13289–94.
- [58] Macotela Y, Emanuelli B, Bang AM, Espinoza DO, Boucher J, Beebe K, et al. Dietary leucine—an environmental modifier of insulin resistance acting on multiple levels of metabolism. *PLoS One* 2011;6(6):e21187.
- [59] Lynch CJ, Fox HL, Vary TC, Jefferson LS, Kimball SR. Regulation of amino acid-sensitive TOR signaling by leucine analogues in adipocytes. *J Cell Biochem* 2000;77(2):234–51.
- [60] Babu E, Kanai Y, Chairoungdua A, Kim DK, Iribe Y, Tangtrongsup S, et al. Identification of a novel system L amino acid transporter structurally distinct from heterodimeric amino acid transporters. *J Biol Chem* 2003;278(44):43838–45.
- [61] Deves R, Boyd CA. Surface antigen CD98(4F2): not a single membrane protein, but a family of proteins with multiple functions. *J Membr Biol* 2000;173(3):165–77.
- [62] Kanai Y, Segawa H, Miyamoto K, Uchino H, Takeda E, Endou H. Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). *J Biol Chem* 1998;273(37):23629–32.

- [63] Segawa H, Fukasawa Y, Miyamoto K, Takeda E, Endou H, Kanai Y. Identification and functional characterization of a Na⁺-independent neutral amino acid transporter with broad substrate selectivity. *J Biol Chem* 1999;274(28):19745–51.
- [64] Nicklin P, Bergman P, Zhang B, Triantafellow E, Wang H, Nyfeler B, et al. Bidirectional transport of amino acids regulates mTOR and autophagy. *Cell* 2009;136(3):521–34.
- [65] Martin JF, Hersperger E, Simcox A, Shearn A. Minidiscs encodes a putative amino acid transporter subunit required non-autonomously for imaginal cell proliferation. *Mech Dev* 2000;92(2):155–67.
- [66] Reynolds B, Roversi P, Laynes R, Kazi S, Boyd CA, Goberdhan DC. *Drosophila* expresses a CD98 transporter with an evolutionarily conserved structure and amino acid-transport properties. *Biochem J* 2009;420(3):363–72.
- [67] Christie GR, Hajdudich E, Hundal HS, Proud CG, Taylor PM. Intracellular sensing of amino acids in *Xenopus laevis* oocytes stimulates p70 S6 kinase in a target of rapamycin-dependent manner. *J Biol Chem* 2002;277(12):9952–7.
- [68] Bauchart-Thévret C, Cui L, Wu G, Burrin DG. Arginine-induced stimulation of protein synthesis and survival in IPEC-J2 cells is mediated by mTOR but not nitric oxide. *Am J Physiol Endocrinol Metab* 2010;299(6):E899–909.
- [69] Colombani J, Raisin S, Pantalacci S, Radimerski T, Montagne J, Leopold P. A nutrient sensor mechanism controls *Drosophila* growth. *Cell* 2003;114(6):739–49.
- [70] Boll M, Foltz M, Rubio-Aliaga I, Kottra G, Daniel H. Functional characterization of two novel mammalian electrogenic proton-dependent amino acid cotransporters. *J Biol Chem* 2002;277(25):22966–73.
- [71] Rubio-Aliaga I, Boll M, Vogt Weisenhorn DM, Foltz M, Kottra G, Daniel H. The proton/amino acid cotransporter PAT2 is expressed in neurons with a different subcellular localization than its paralog PAT1. *J Biol Chem* 2004;279(4):2754–60.
- [72] Sagne C, Agulhon C, Ravassard P, Darmon M, Hamon M, El Mestikawy S, et al. Identification and characterization of a lysosomal transporter for small neutral amino acids. *Proc Natl Acad Sci USA* 2001;98(13):7206–11.
- [73] Goberdhan DC, Meredith D, Boyd CA, Wilson C. PAT-related amino acid transporters regulate growth via a novel mechanism that does not require bulk transport of amino acids. *Development* 2005;132(10):2365–75.
- [74] Metzner L, Neubert K, Brandsch M. Substrate specificity of the amino acid transporter PAT1. *Amino Acids* 2006;31(2):111–7.
- [75] Heublein S, Kazi S, Ogmundsdottir MH, Attwood EV, Kala S, Boyd CA, et al. Proton-assisted amino-acid transporters are conserved regulators of proliferation and amino-acid-dependent mTORC1 activation. *Oncogene* 2010;29(28):4068–79.
- [76] Flinn RJ, Yan Y, Goswami S, Parker PJ, Backer JM. The late endosome is essential for mTORC1 signaling. *Mol Biol Cell* 2010;21(5):833–41.
- [77] Kim E, Goraksha-Hicks P, Li L, Neufeld TP, Guan KL. Regulation of TORC1 by Rag GTPases in nutrient response. *Nat Cell Biol* 2008;10(8):935–45.
- [78] Sancak Y, Bar-Peled L, Zoncu R, Markhard AL, Nada S, Sabatini DM. Ragulator–Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. *Cell* 2010;141(2):290–303.
- [79] Nada S, Hondo A, Kasai A, Koike M, Saito K, Uchiyama Y, et al. The novel lipid raft adaptor p18 controls endosome dynamics by anchoring the MEK–ERK pathway to late endosomes. *EMBO J* 2009;28(5):477–89.
- [80] Zoncu R, Bar-Peled L, Efeyan A, Wang S, Sancak Y, Sabatini DM. mTORC1 senses lysosomal amino acids through an inside-out mechanism that requires the vacuolar H-ATPase. *Science* 2011;334(6056):678–83.
- [81] Ohsaki Y, Suzuki M, Shinohara Y, Fujimoto T. Lysosomal accumulation of mTOR is enhanced by rapamycin. *Histochem Cell Biol* 2010;134(6):537–44.
- [82] Korolchuk VI, Saiki S, Lichtenberg M, Siddiqi FH, Roberts EA, Imarisio S, et al. Lysosomal positioning coordinates cellular nutrient responses. *Nat Cell Biol* 2011;13(4):453–60.
- [83] Settembre C, Di Malta C, Polito VA, Garcia Arencibia M, Vetrini F, Erdin S, et al. TFEB links autophagy to lysosomal biogenesis. *Science* 2011;332(6036):1429–33.
- [84] Pena-Llopis S, Vega-Rubin-de-Celis S, Schwartz JC, Wolff NC, Tran TA, Zou L, et al. Regulation of TFEB and V-ATPases by mTORC1. *EMBO J* 2011;30(16):3242–58.
- [85] Yu L, McPhee CK, Zheng L, Mardones GA, Rong Y, Peng J, et al. Termination of autophagy and reformation of lysosomes regulated by mTOR. *Nature* 2010;465(7300):942–6.
- [86] Kim J, Guan KL. Amino acid signaling in TOR activation. *Annu Rev Biochem* 2011;80:1001–32.
- [87] Yan L, Mieulet V, Burgess D, Findlay GM, Sully K, Procter J, et al. PP2A T61 epsilon is an inhibitor of MAP4K3 in nutrient signaling to mTOR. *Mol Cell* 2010;37(5):633–42.
- [88] Bryk B, Hahn K, Cohen SM, Teleman AA. MAP4K3 regulates body size and metabolism in *Drosophila*. *Dev Biol* 2010;344(1):150–7.
- [89] Resnik-Docampo M, de Celis JF. MAP4K3 is a component of the TORC1 signalling complex that modulates cell growth and viability in *Drosophila melanogaster*. *PLoS One* 2011;6(1):e14528.
- [90] Byfield MP, Murray JT, Backer JM. hVps34 is a nutrient-regulated lipid kinase required for activation of p70 S6 kinase. *J Biol Chem* 2005;280(38):33076–82.
- [91] Xu L, Salloum D, Medlin PS, Saqçena M, Yellen P, Perrella B, et al. Phospholipase D mediates nutrient input to mammalian target of rapamycin complex 1 (mTORC1). *J Biol Chem* 2011;286(29):25477–86.
- [92] Yoon MS, Du G, Backer JM, Frohman MA, Chen J. Class III PI-3-kinase activates phospholipase D in an amino acid-sensing mTORC1 pathway. *J Cell Biol* 2011;195(3):435–47.